Corcept Therapeutics

Yahoo Finance • 16 hours ago

December 2025's Top Insider-Owned Growth Stocks

As the U.S. stock market continues to hit new highs, with the S&P 500 setting an all-time record and major indices posting consistent gains, investors are keenly observing growth opportunities. In this thriving environment, companies with... Full story

Yahoo Finance • 5 days ago

Top picks for 2026 from top-performing funds - Barron's

[Metallic 2026 Written Over Financial Chart Background] mustafaU In a year where beating the market has proven challenging, a select group of stock fund managers have found winning strategies. They shared where they see opportunities ahea... Full story

Yahoo Finance • 7 days ago

Top Growth Companies With Strong Insider Ownership December 2025

As the U.S. stock market faces a downturn with major indexes like the S&P 500 and Dow Jones Industrial Average posting consecutive losses, investors are increasingly cautious about tech stocks amid concerns of an AI bubble. In such volatil... Full story

Yahoo Finance • 9 days ago

3 Growth Companies With High Insider Ownership And 13% Revenue Growth

As the U.S. stock market experiences a pullback with major indices like the S&P 500 and Dow Jones facing consecutive losses, investors are increasingly cautious amid concerns over an AI bubble and tepid labor data. In such uncertain times,... Full story

Yahoo Finance • 11 days ago

Alger Russell Innovation Index Updates for Fourth Quarter 2025

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close... Full story

Yahoo Finance • 15 days ago

Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C. Wainwright reiterated a Buy rating and a $145 price target on the stock, citing its strong gro... Full story

Yahoo Finance • 18 days ago

Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the best stocks you’ll wish you bought sooner. As of the close of December 2, the consensus shows that analyst opinions are highly favourable towards Corcept Therapeutics Incorporat... Full story

Yahoo Finance • 25 days ago

Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.16%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.41%. Stock indexes today are posting moderate losses, with the Dow Jones... Full story

Yahoo Finance • 30 days ago

Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a must-buy non-tech stock to invest in. On November 17, analysts at Wolfe Research initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) with a Peer Perform rating. Accordi... Full story

Yahoo Finance • last month

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fu... Full story

Yahoo Finance • 2 months ago

Corcept anticipates $3B–$5B annual hypercortisolism revenue with relacorilant as FDA decisions near

Earnings Call Insights: Corcept Therapeutics (CORT) Q3 2025 MANAGEMENT VIEW * Joseph K. Belanoff, CEO, stated that “we are on the cusp of a new era at Corcept,” highlighting the company’s two New Drug Applications (NDAs) approaching FD... Full story

Yahoo Finance • 3 months ago

FDA Accepts New Drug Application for Corcept Therapeutics’s (CORT) Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the FDA has accepted its new drug applica... Full story

Yahoo Finance • 3 months ago

Alger Russell Innovation Index Updates for Third Quarter 2025

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the clos... Full story

Yahoo Finance • 4 months ago

Corcept's ovarian cancer treatment under FDA review

[Ovary cancer] Raycat/iStock via Getty Images * Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment... Full story

Yahoo Finance • 4 months ago

Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts. On August 14, analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics Incorporat... Full story

Yahoo Finance • 4 months ago

Plant Breeding and CRISPR Plants Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Breeding, Crop Protection, and Agricultural Innovation

Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Plant Breeding and CRISPR Plants - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Breeding and CRISPR Plants Companies Quadrant is... Full story

Yahoo Finance • 4 months ago

Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Plant Biotechnology - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Biotechnology Companies Quadrant is a comprehensive industry... Full story

Yahoo Finance • 4 months ago

Corcept therapeutics officer sells $2.5M in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 35,007 shares of common stock on August 8, 2025, for $71.77, totaling approximately $2.5 million. The sale was executed under a prearranged 10b5-1 t... Full story

Yahoo Finance • 5 months ago

Corcept therapeutics officer Lyon sells $393k in shares

Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics (NASDAQ:CORT), sold 5,823 shares of common stock on August 1, 2025, for approximately $393,127. The shares were sold at a weighted average price of $67.51... Full story

Yahoo Finance • 5 months ago

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 11 Best Long Term Low Risk Stocks to Invest in. The company completes a key drug study and has submitted a new drug application to the U.S. FDA.Corcept Therapeutics Advances Pi... Full story